Flavocure Biotech

Next Generation Medicines Inspired by Nature

What we do

Flavocure

Flavocure Biotech Inc. aims to be a leader in transforming natural products into new cures for patients.

The company has discovered several promising new drug candidates. In collaboration with some of the most prestigious research institutions in the world, Flavocure is advancing these candidates through clinical research. Preliminary data indicate that Flavocure’s drug candidates possess activity against known driver mutations and targets implicated in cancer.

Caflanone is Flavocure’s lead drug candidate and received FDA Orphan Drug Designation in 2019 for pancreatic cancer.

In addition to pancreatic cancer, Flavocure’s drug candidates have demonstrated activity in a variety of cancers, including Glioblastoma (an aggressive form of brain cancer), Acute Myeloid Leukemia, and Multiple Myeloma.

Oncology Pipeline

Product	Target	Disease	Developmental Stage	Research Partners
Caflanone	CSF1R	Pancreatic Cancer	IND ready FDA-ORPHAN Drug Designation	Ongoing
Caflanone	CSF1R	GBM/Myeloma	Pre-Clinical	Ongoing
Cresorol	FLT3	AML	FDA-ORPHAN Drug Designation	Ongoing

Our Research

Focus Areas

Pancreatic Cancer

GBM

Myeloma

AML

In the US, SEER reported pancreatic cancer as the 11^th most common cancer with 60,430 new cases and 48,220 deaths in 2022. Pancreatic cancer statistics highlight a dire need for transformative therapies for this lethal disease

2022 US Pancreatic Cancer Statistics

New Cases: 60,430
Deaths: 48, 220
Accounts for 3% of all cancers, and 7% of all cancer deaths
5-year relative survival of 10.8%
Median Age at diagnosis: 70
Median age at death: 72

Glioblastoma or brain cancer is considered a very dire prognosis for patients. In the US, SEER reported cancers of the brain and other nervous systems to be 16^th most common cancer with 25,051 new cases and 18,280 deaths in 20222.

2022 Brain and other nervous system cancer statistics

New cases: 20,050
Deaths: 18,280
Accounts for 1.3% of all cancers, and 3% of all cancer deaths
5-year relative survival of 32.5%
Median age at diagnosis: 59
Median age at death: 66

Myeloma is a type of blood cancer that develops from plasma cells, a type of white blood cells. In the US, SEER reported Myeloma to be the 14^th most common cancer with 34,470 new cases and 12,640 deaths in 2022.

2022 Myeloma statistics

New cases: 34,470
Deaths: 12,640
Accounts for 1.8% of all cancers, and 2.1% of all cancer deaths
5-year relative survival of 57.9.5%
Median age at diagnosis: 69
Median age at death: 75

AML is a type of blood cancer that starts in the blood forming cells of the bone marrow. In the US SEER reported AML to be relatively rare cancer with 20,050 new cases and 11,540 deaths in 2022

2022 AML statistics